Published in Medical Letter on the CDC and FDA, February 18th, 2007
The primary objective of the trial was to determine the optimal dose of Droxidopa in the treatment of orthostatic hypotension in patients with multiple system atrophy (MSA) or Parkinson disease (PD). The double-blind, randomized, placebo-controlled, parallel group, Phase IIb trial, led by Christopher Mathias, DPhil, DSc, FRCP, professor of neurovascular medicine, Imperial College School of Medicine at St. Mary's Hospital, London, was conducted at 30...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.